Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 9/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1236491 | 0.83 | ALDH1A1 (0.66) | CYP1A2CYP1A1CYP1B1ALDH1A1TRIM24 | |
| SCHEMBL16093963 | 0.82 | CYP1A2 (0.47) | CYP1A2CYP1A1CYP1B1ALDH1A1TRIM24 | |
| SCHEMBL28761484 | 0.82 | CYP1A1 (0.47) | CYP1A2CYP1A1CYP1B1ALDH1A1TRIM24 | |
| Hydrochloric Acid SCHEMBL968280 | 0.80 | CYP1A2 (0.46) | CYP1A2CYP1A1CYP1B1ALDH1A1TRIM24 | |
| SCHEMBL11266435 | 0.77 | KMT2A (0.61) | CYP1A2CYP1A1CYP1B1ALDH1A1TRIM24 | |
| SCHEMBL14422185 | 0.77 | TRIM24 (0.43) | CYP1A2CYP1A1CYP1B1ALDH1A1TRIM24 | |
| SCHEMBL11266428 | 0.77 | KMT2A (0.61) | CYP1A2CYP1A1CYP1B1ALDH1A1TRIM24 | |
| SCHEMBL3604055 | 0.77 | TRIM24 (0.43) | CYP1A2CYP1A1CYP1B1ALDH1A1TRIM24 | |
| SCHEMBL1547597 | 0.77 | CYP1A2 (0.73) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL9026006 | 0.76 | CYP1A2 (0.53) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-04-29 | — | — | US | claimed |
| EP-1686996-A4 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-11-12 | — | — | EP | claimed |
| US-7368453-B2 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | claimed |
| JP-2007511612-A | — | — | 2007-05-10 | — | — | JP | claimed |
| EP-1686996-A1 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | CHIRON CORPORATION (US) | 2006-08-09 | — | — | EP | claimed |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION GLAXOSMITHKLINE | 2005-09-01 | — | — | US | claimed |
| WO-2005051391-A1 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | CHIRON CORPORATION (US) | 2005-06-09 | — | — | WO | claimed |
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-7625909-B2 | Substituted quinazolinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1686996-A4 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7368453-B2 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1686996-A1 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | CHIRON CORPORATION (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1651229-A1 | GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS | Chiron Corporation (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION GLAXOSMITHKLINE | 2005-09-01 | — | — | US | disclosed |
| WO-2005051391-A1 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | CHIRON CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050059662-A1 | Substituted quinazolinone compounds | CHIRON CORPORATION | 2005-03-17 | — | — | US | disclosed |
| WO-2004112793-A1 | GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059662-A1 | Substituted quinazolinone compounds | MC4R, MC2R, MC3R | CYP1A2 2636/4885CYP1A1 1761/4885CYP1B1 2743/4885 |
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | MC4R, MC5R, MC2R | CYP1A2 2110/4885CYP1A1 1701/4885CYP1B1 1845/4885 |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | MC4R, MC2R, MC3R | CYP1A2 255/4885CYP1A1 144/4885CYP1B1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.